Informations:
Erreur:
ID
18412
Description
SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00076349
Lien
https://clinicaltrials.gov/show/NCT00076349
Mots-clés
Versions (1)
- 03/11/2016 03/11/2016 -
Téléchargé le
3 novembre 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Non-Hodgkin's Lymphoma NCT00076349
Eligibility Non-Hodgkin's Lymphoma NCT00076349
- StudyEvent: Eligibility
Similar models
Eligibility Non-Hodgkin's Lymphoma NCT00076349
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
B-Cell Lymphomas | Mantle cell lymphoma
Item
documented b-cell nhl or mantle cell lymphoma
boolean
C0079731 (UMLS CUI [1])
C0334634 (UMLS CUI [2])
C0334634 (UMLS CUI [2])
Malignant Neoplasm CD20 antigen positive
Item
cd-20+ tumor
boolean
C0006826 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
C3888518 (UMLS CUI [1,2])
indolent lymphoma | Lymphoma, Follicular | Small Lymphocytic Lymphoma | Marginal Zone B-Cell Lymphoma
Item
indolent nhl: follicular b-cell lymphoma, diffuse small lymphoma, marginal zone lymphoma
boolean
C1334170 (UMLS CUI [1])
C0024301 (UMLS CUI [2])
C0855095 (UMLS CUI [3])
C1367654 (UMLS CUI [4])
C0024301 (UMLS CUI [2])
C0855095 (UMLS CUI [3])
C1367654 (UMLS CUI [4])
Prior Chemotherapy Quantity Maximum
Item
maximum of three prior chemotherapy regimens
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
Age
Item
age of at least 18 years at screening visit (site specific requirement may differ)
boolean
C0001779 (UMLS CUI [1])
rituximab refractory | Disease Progression | rituximab Single | rituximab Combined
Item
refractory to rituximab, defined as progression of disease while being treated with rituximab or progression within 6 months of the last dose of rituximab (when given either as a single agent or in combination)
boolean
C0393022 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C0393022 (UMLS CUI [3,1])
C0205171 (UMLS CUI [3,2])
C0393022 (UMLS CUI [4,1])
C0205195 (UMLS CUI [4,2])
C0205269 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C0393022 (UMLS CUI [3,1])
C0205171 (UMLS CUI [3,2])
C0393022 (UMLS CUI [4,1])
C0205195 (UMLS CUI [4,2])
Prior Chemotherapy | Prior Immunotherapy | Nitrosourea | Mitomycin | Adverse reaction to drug | Recovering failed
Item
previous chemotherapy or immunotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin) or failure to recover from adverse events due to any agents administered previously
boolean
C1514457 (UMLS CUI [1])
C1514461 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
C0002475 (UMLS CUI [4])
C0041755 (UMLS CUI [5])
C0521108 (UMLS CUI [6,1])
C0231175 (UMLS CUI [6,2])
C1514461 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
C0002475 (UMLS CUI [4])
C0041755 (UMLS CUI [5])
C0521108 (UMLS CUI [6,1])
C0231175 (UMLS CUI [6,2])
Investigational New Drugs
Item
use of investigational agents within 28 days of study
boolean
C0013230 (UMLS CUI [1])
Prior Chemotherapy High dose | Allogeneic Stem Cell Transplantation
Item
history of prior high dose chemotherapy with allogeneic stem cell support
boolean
C1514457 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C2242529 (UMLS CUI [2])
C0444956 (UMLS CUI [1,2])
C2242529 (UMLS CUI [2])
Radioimmunotherapy
Item
history of prior radioimmunotherapy
boolean
C0085101 (UMLS CUI [1])